Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706684 | 0.91 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNASLC15A2NPC1 | |
| SCHEMBL12723334 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL18900660 | 0.78 | TDP1 (0.36) | KMT2ALMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL3715609 | 0.77 | TSHR (0.33) | ALDH1A1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL18900575 | 0.77 | — | — | |
| SCHEMBL12897268 | 0.77 | KMT2A (0.47) | ALDH1A1KMT2ALMNAPOLBUSP2 | |
| SCHEMBL21747305 | 0.77 | ALDH1A1 (0.31) | ALDH1A1KMT2A | |
| SCHEMBL11610955 | 0.76 | KMT2A (0.34) | ALDH1A1KMT2AHPGD | |
| SCHEMBL26553932 | 0.76 | PAOX (0.41) | ALDH1A1LMNASLC15A2SMN1; SMN2TP53 | |
| SCHEMBL16287309 | 0.75 | KMT2A (0.42) | ALDH1A1KMT2ALMNAPOLBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588486-B1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | CENTRE NAT RECH SCIENT (FR) | 2017-05-31 | — | — | EP | claimed |
| US-20130158219-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | UNIVERSITE DE BOURGOGNE (FR) | 2013-06-20 | — | — | US | claimed |
| EP-2588486-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | Centre National De La Recherche Scientifique (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001601-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-05 | — | — | WO | claimed |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-3613742-B1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-9045511-B2 | Supported ligands having a high local density of coordinating atoms | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-02 | — | — | US | disclosed |
| US-9045511-B2 | Supported ligands having a high local density of coordinating atoms | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-02 | — | — | US | disclosed |
| US-20130158219-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | UNIVERSITE DE BOURGOGNE (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158219-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | UNIVERSITE DE BOURGOGNE (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158219-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | UNIVERSITE DE BOURGOGNE (FR) | 2013-06-20 | — | — | US | disclosed |
| EP-2588486-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | Centre National De La Recherche Scientifique (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012001601-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012001601-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
| US-20130158219-A1 | SUPPORTED LIGANDS HAVING A HIGH LOCAL DENSITY OF COORDINATING ATOMS | SLC40A1, FECH, IDH2 | ALDH1A1 3053/4885KMT2A 827/4885LMNA 4587/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | ALDH1A1 1770/4885KMT2A 2472/4885LMNA 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.